Hidemaru Yamaguchi's questions to Takeda Pharmaceutical Co Ltd (TAK) leadership • Q1 2025
Question
Hidemaru Yamaguchi from Citi asked if the strong Q1 performance of the dengue vaccine, QDENGA, was due to any one-time factors or if it represents a new baseline. He also inquired if the Q1 earnings progress, excluding currency and VYVANSE, was in line with full-year expectations.
Answer
President and CEO Christophe Weber stated that QDENGA's strong start reflects significant underlying demand, with manufacturing capacity being the current limiting factor, and was not driven by one-time events. CFO Milano Furuta confirmed that overall Q1 progress was on track, with top-line performance as expected and R&D expenses phased for later in the year, thus justifying the unchanged guidance.